Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

32.65
-0.0100-0.03%
Post-market: 32.970.3200+0.98%19:59 EDT
Volume:3.08M
Turnover:98.95M
Market Cap:2.80B
PE:-7.52
High:32.99
Open:31.95
Low:30.96
Close:32.66
Loading ...

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Apr

Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says

MT Newswires Live
·
03 Apr

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
03 Apr

CRISPR Therapeutics Ag : RBC Cuts Target Price to $38 From $48

THOMSON REUTERS
·
03 Apr

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire
·
03 Apr

RBC Cuts Price Target on CRISPR Therapeutics to $38 From $48, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
03 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today

Motley Fool
·
01 Apr

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks
·
31 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakers

Reuters
·
31 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

CRISPR Therapeutics (NasdaqGM:CRSP) COO Departure Announced Following 7% Share Price Decline

Simply Wall St.
·
28 Mar

CRISPR Therapeutics COO to Step Down

MT Newswires Live
·
27 Mar

Crispr Therapeutics COO Julianne Bruno to step down

TIPRANKS
·
27 Mar

Press Release: CRISPR Therapeutics Announces Transition of Chief Operating Officer

Dow Jones
·
27 Mar

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

GlobeNewswire
·
26 Mar

This CRISPR Therapeutics Insider Increased Their Holding In The Last Year

Simply Wall St.
·
26 Mar

Is CRISPR Therapeutics AG (CRSP) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

2 Beaten-Down Stocks to Buy on the Dip

Motley Fool
·
23 Mar

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

Zacks
·
21 Mar